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The etiology of many neurological cases cannot be easily delineated, making the investigation, and 
treatment to be challenging. This study aims to screen the blood of neurology patients presenting for 
the first time in the hospital for Polycyclic Aromatic Hydrocarbons (PAHs) using Flame Ionization 
Detector – Gas Chromatography. Fourteen PAHs were detected in the samples. The results showed that 
flourene and phenanthrene were common to all the patients in the range (1.37 to 8.08 and 1.66 to 8.34 
ng/mL respectively), but were not detected in the control samples. Pyrene, fluoranthene and 
acenaphthene were present in 80, 75 and 70% in the blood plasma of the patients at the range of 2.96 to 
236.86 ng/mL, 1.96 to 11.55 ng/mL and  1.08 to 1.81 ng/mL respectively. These were not found in the 
control samples. The body burden of these congeners was much higher in neurology patients than 
controls and literature values of similar study. The concentrations detected were statistically 
significant, and could be possible causative agents. This can also become one of the investigative tools 
for these diseases.  
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INTRODUCTION 
 
Polycyclic Aromatic Hydrocarbons (PAHs) are a large 
group of ubiquitous and environmentally persistent 
organic compounds. They are formed by thermal 
decomposition such as in burning of coal, exhaust 
engines, garbage, wood, or other organic substances 
such as tobacco and smoked fish or meat (ATSDR, 1995; 
Pleil et al., 2010). They  are  present  in  air,  water,  food,  
dust, soot and so represent a constant flow level of 
exposure to human via skin contact, inhalation and 
ingestion (Farhadian et al., 2011). 
They are chemically related contaminants that are of 
various structures and varied toxicity. They exist as 
volatile, semi-volatile and non- volatile organic 
compounds. They are ranked number nine in  the  priority  
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list of hazardous substances. Over the years Polycyclic 
Aromatic Hydrocarbons (PAHs) have received much 
attention because they are suspected to be carcinogenic 
and they also induce human inflammatory mediated 
diseases (CDC, 2009; Sexton et al., 2007; Lewtas, 2007; 
Schober et al., 2007). They have been implicated in 
adverse reproductive outcomes, somatic mutations and 
decrease in children’s IQ (Sram et al., 1999; Perera et al., 
2002). Inhalation of PAHs from diesel engine exhaust has 
been linked with pulmonary cytokine expression (Sobus 
et al., 2008; Swanson et al., 2009). Due to their 
carcinogenic activity, PAHs have been included in the 
European Union (EU) and the United States 
Environmental Protection Agency (USEPA) priority 
pollutant lists. 
The body burden of PAHs had been assessed in urine 
(Hansen et al. 2008). The analysis for PAHs as potential 
biomarker and measurement of aliphatic hydrocarbon, 
single ring aromatic compound as well as analysis of 
PAHs in blood headspace had been reported (Chambers 
et al., 2008; Kim et al., 2006; Gyorffy et al., 2008). Pleil et 
al. (2010) analyzed blood and plasma of healthy people 
to determine PAHs and found them at varying 
concentrations.  
Neurology disease is a disease that affects the nervous 
system, structural, biochemical or electrical abnormalities 
in the brain, spinal cord and nerves. Symptoms may 
include paralysis, seizures, confusion, loss of sensation 
and many others. Since PAHs had been implicated of 
reducing children’s IQ (Perera et al., 2002) and neurology 
diseases affect the brain and the nervous system, it is 
pertinent to investigate whether there is a link between 
the pollutant and the disease. 
In this study, blood plasma of twenty neurology patients 
and 12 plasma of healthy subjects were analyzed for 
PAHs to determine how the concentration levels 
compared with literature values of healthy subjects. 
The concentration levels will give an assessment of the 
PAHs toxicity levels in the patients compared to literature 
values of healthy subjects and the healthy subjects used 
as controls. 
 
 
MATERIALS AND METHODS 
 
The out patients neurology clinic of the Obafemi Awolowo 
University Teaching Hospital, Ile-Ife, Nigeria was used for sampling 
twenty neurology patients experiencing it for the first time  
 
 
Sampling 
 
Ten milliliters of whole blood was collected via the vein using 
syringe and needles in heparinized bottle and transferred to the 
laboratory and centrifuged. The plasma was immediately 
transferred to 20 mL capacity amber bottles to prevent sample 
degradation, PAHs being UV light – sensitive. These were stored in  
 
 
 
 
the refrigerator at 4°C prior to extraction. 
 
 
Sample extraction and clean up 
 
Liquid - liquid extraction technique was employed using ratio 4:1 n-
hexane and Dichloromethane (DCM). The extractant (10 mL) and 
plasma samples (2 mL) were added in the vials, capped and vortex 
for 20 s at 300 rpm. The organic layer was sucked out using pipette 
attached with pipette filler into clean and thermally treated amber 
bottles. The extracts were cleaned up in a column (1 cm x 15 cm, 
internal diameter and length) with slurry of silica gel as stationary 
phase, preconditioned by distilled water and hexane/DCM before 
the samples were eluted, collected and concentrated in a stream of 
nitrogen gas.  
 
 
Sample analysis 
 
Samples were analyzed after reconstitution with hexane/DCM at 
Nigerian Institute of Oceanography and Marine Research (NIOMR) 
Lagos. The standards of the congeners were supplied and 
analyzed and used to identify and quantify the PAHs in the 
samples. The corresponding relative retention time with respect to 
each congener was used to identify each PAH by Gas 
Chromatography Flame Ionization Detector (GC- FID) using Agilent 
Model 7890A (Agilent Technologies, Delaware, MD. USA). 
Separation was carried out in a GC column HP-5 (Agilent; 30 m × 
320 µm × 0.25 µm film thickness) using a temperature programmed 
GC for elution of analytes. The column temperature was set initially 
at 60°C and held for 1 min. This was ramped to 210°C at 12°C/min 
and increased to 320°C at 8°C/min held for 5 min. The total run 
time was 32.25 min and the detector temperature was 325°C. The 
flow rate was 1.2 ml/min with injection volume of 1 µL. The inlet 
mode was splitless with temperature of 270°C. 
 
 
RESULTS AND DISCUSSION 
 
PAHs concentrations 
 
All twenty patients sampled were found positive to PAHs 
and exhibited wide variations in concentrations. The 
United States Environmental Protection Agency (USEPA) 
classified 16 PAHs as priority pollutants because they are 
common in environmental media, toxic and they can 
easily be absorbed by humans (EPA, 2010). Fourteen out 
of these sixteen on EPA priority list were detected in the 
neurology patients' plasma and only six PAHs were 
detected in the plasma of control subjects. Out of the 
twelve healthy subjects, six were positive to pyrene, two 
to chrysene, two to Benzo[b]fluoranthrene, six to 
Benzo[k] fluoranthrene  and three were positive to 
Benzo(g,h,i)perylene which was not detected in the 
patients. Table 1 shows the mean concentrations of 
various congeners in the samples. The result shows that, 
18 of the patients (80%) had pyrene at varying 
concentrations in the plasma, 75% had fluoranthrene and 
70% had acenaphthene. Fluorene and phenanthrene 
were present in all the patients screened. With the 
exception of acenaphthene, the above four  analytes  had  
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Table 1. Statistical comparison of the concentrations of PAHs in plasma of neurology patients with the normal subjects in the literature. 
 
PHAs 
This study Pleila et al. 2010 (EPA) Singh 2008 
Patient Plasma, n=20, Control Plasma, n= 12 Plasma fraction, n=19 Plasma fraction, n=10 Plasma fraction, n=30 Blood Fraction, 
n=56 Patient subjects Control Subjects Study subjects Student subjects Sera care (Reference) 
ng/mL (ng/mL=103 
pg/mL) 
ng/mL(ng/mL= 
103pg/mL) 
pg/mL pg/mL Pg/mL Pg/mL 
Mean Median C-mean C-median Median Max Min Median Max Min Median Max Min Median 
Naphthalene 6.17 6.08 - - 779 12292 149 183 513 68 1459 3290 257 21660 
Acenaphthalene 0.45 - - - 93 179 19 10 75 7 21 486 4 7192 
Acenaphthene  0.84 1.15 - - 854 1578 174 15 191 - 29 207 6 - 
Fluorene 3.49 2.82 - - 81 416 19 14 95 8 46 261 22 - 
Anthracene 2.49 - - - 181 562 12 12 122 - 10 21 - 4500 
Phenanthrene 3.92 3.39 - - 330 1793 52 42 170 19 75 245 45 9567 
Fluoranthene 2.57 2.29 - - 142 1076 36 17 137 7 27 185 7 7500 
Pyrene 24.72 8.98 2.36 2.01 243 392 75 13 197 7 54 376 7 11439 
benz[a]anthracene 1.64 - 2.79 2.34 47 246 - 4 38 - 3 9 - - 
Chrysene 3.46 - 0.222 0.222 46 386 - 3 88 - 3 10 - - 
benzo[b]fluoranthrene 4.32 - 4.43 3.65 16 111 4 - 13 - 11 51 3 5401 
benzo[k]fluoranthrene 3.95 - 2.32 2.14 50 192 - 7 40 - 19 78 3 5144 
benzo[a]pyrene 31.71 31.71 - - 19 195 - 4 17 - 18 119 5 1736 
dibenz[a,h]anthracene 13.79 13.97 - - 39 180 - - 14 - 40 144 7 - 
Benzo(g,h,i)perylene - - 10.34 10.077 - - - - - - - - - - 
 
 
 
been classified by EPA (2010) as group D of 
carcinogens and International Agency for 
Research on Cancer (IARC) (2009) classified 
them as number 3 potential carcinogens but they 
were not present in the control subjects. 
But two patients had Benzo(a)pyrene in the 
plasma with concentration above the acceptable 
limit of 0.1 µg/L Toxicity Equivalent Factor as 
recommended by EPA (2010). It is a potent 
carcinogen and generally used as an  
environmental indicator for PAHs.  
Skupinska et al. (2004) stated that size 
influences the fate of the gaseous PAHs mixtures. 
Those that are more than four  rings  are  heavier, 
because they are particulates and tend to adsorb 
on the environmental media, while the PAHs that 
are less than four rings tend to remain in the 
gaseous state until removed via precipitation. The 
majority of PAHs analyzed in this study are less 
than or equal to four rings (about ten), hence, 
inhalation may likely be one major route of 
absorption by the patients due to PAHs emission  
while drinking of shallow well water might be a 
minor source because of their low solubility in 
water. Leaching of bitumen used in road 
construction to surface water could also be an 
additional source. 
The mean concentrations of the PAHs in all  the  
patients are summarized in Figure 1. Pyrene 
concentration constitutes 43% of all the PAHs 
concentrations in all the patients, being found in 
18 patients. The geometric mean of plasma 
concentrations of pyrene in this study was 11.33 
ng/mL with maximum concentration of 236.86 
ng/mL. Its urinary metabolite, 1-hydroxypyrene, 
had been used as an indicator of exposure to 
PAHs chemicals (Popp, 1997; CDC, 2005).  This 
metabolite was recommended for measurement 
as end-of-work-week urine samples by The 
American Conference of Governmental Industrial 
Hygienists (ACGIH) as biological exposure index 
(BEI) for assessment of exposure to mixtures
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Figure 1. Percentage composition of PAHS in blood of neurology patients. 
 
 
 
containing PAHs (Heikkila et al., 1995; ACGIH, 2005). 
Since the relative amounts of PAH congeners in mixtures 
vary from place-to place, this does not provide direct 
information on the relationship between exposure to 
pyrene and urinary 1-hydroxypyrene concentrations 
(Alghamdi et al., 2015). Like most PAHs, pyrene is used 
to make dyes, plastics and pesticides. It has also been 
used to make another PAH called Benzo(a)pyrene 
(ATSDR, 1990; Faust, 1993). Pyrene as a common 
chemical in materials that are daily been used could 
make people to be more exposed, lifestyle of the patients 
and occupation could also play a major role in high 
percentage constitution. 
As shown in this study, the statistical concentrations of 
PAH’s found in the patients, and an earlier study of 
regular subjects by Pleila et al. (2010) and Seracare (the 
reference blood sample)’, it is evident that the body 
burden of PAH’s in the blood of the neurology patients is 
higher.  The individual value in this study measured at 
ng/mL as compared with the literature values in (Table 1) 
measured in pg/mL showed the high concentration at 
which the PAHs were present in the neurology patients. 
Figure 2 shows the levels of the difference, what was 
found in the neurology patients (Blue colour) were higher 
than the literature values. The bio accumulative effect of 
the volatile and particulate forms of these PAHs may be 
capable of neurological damage. 
 
 
Correlation of PAHs in the samples 
 
Rappaport et al. (2005), in their study, proposed 
Naphthalene as an alternate biomarker for the 
determination of PAHs in the body and the metabolites 1-
and 2‐hydroxynapthalene in urine as an alternative to 1‐
hydroxypyrene. Since naphthalene (two ring PAHs) 
sublimes into gaseous state, it will be a suitable 
biomarker for industrial exposure to airborne PAHs 
mixtures. AIOH (2016) suggested that where elevated 
levels of lower ring number PAHs may be present, the 
monitoring and assessment could be done using 
Naphthalene. A proximate matrix of the mixture of PAH 
was done using the mean concentration of the PAHs, 
naphthalene   correlated   with    Phenanthrene    (0.647), 
bitumen used in road construction to surface water could also be an additional source. 
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Figure 2. Maximum Concentrations of PAH's in Neurology Patients and Pleila et al. (2010) study.   
 
 
 
Pyrene (0.595) and Benz(a)Pyrene(0.466) (Table 2). This 
may be a pointer that the source of absorption is not 
predominantly through inhalation, but may be dermal, 
food and air borne.  According to Rappaport et al. (2004) 
where there is a mixture of dermal and airborne 
exposure, an alternative marker correlating better with 
the higher number ring compounds could be more 
suitable as biomarker. Thus, any of the following three 
could be used as biomarker; Phenanthrene, Pyrene and 
Benz (a)Pyrene as corroborated by Sobus et al. (2008).  
Sobus et al. (2009) in their study concluded that levels of 
naphthalene and phenanthrene in urine reflect airborne 
exposures to these compounds and are promising 
surrogates for occupational exposures to PAH mixtures. 
The control samples used in this study were blood 
plasma of undergraduate students (majorly, clinical 
students, >20 ≥30 years); all the three proposed 
biomarkers were absent in the control samples. This 
suggests that the occupation of subjects may play major 
role in the exposure and concentrations of these 
congeners in the body.  In this study, blood plasma was 
used similar to urine in the sense that, they are both body 
fluid that represent the current state or on- going activities 
in the body. Seidel et al. (2008) determined metabolites 
of phenanthrene in post shift urine of occupational 
exposed worker (and concluded that phenanthrene was  
also a reliable biomarker for PAH exposure).The higher 
member ring, especially, B[a]pyrene; a potential 
carcinogen correlates with 5 other PAHs (Naphthalene, 
Pyrene, Benzo (a) Anthracene, Chrysene and 
benzo[k]fluoranthrene), of which Benzo (a) Anthracene, 
Chrysene and benzo[k]fluoranthrene were classified as 
possible carcinogens (IARC, 2010). This suggests that 
they have common possible source. The high values of 
these PAHs give course for concern as they have been 
implicated as being carcinogenic. 
 
 
Risk assessment 
 
The Toxicity Equivalency Factor (TEF) methodology was 
developed by the U.S. Environmental Protection Agency 
(EPA) to evaluate the toxicity and assess the risks of a 
mixture of structurally related chemicals with a common 
mechanism of action. A TEF is an estimate of the relative 
toxicity of a chemical compared to  a  reference  chemical  
1 
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Table 2. Proximity Matrix of Mixture of PAHs in Neurology Patients.       
 
 Nap Aclene- Acthene Fluo Anthra Phnant Fluoran. Pyre B (a)A Chrys B(b)F B(k)F B(a)P DB(a,h)A. 
Nap 10.000              
Aclene- -0.098 10.000             
Acthene. 060 -0.108 10.000            
Fluo 0.122 0.058 0.220 10.000           
Anthra -0.234 0.290 0.404 -0.178 10.000          
Phnant 0.647 -0.245 0.261 0.451 -0.479 10.000         
Fluoran. 138 -0.013 -0.386 -0.035 -0.025 -0.251 10.000        
Pyre 0.595 -0.119 -0.352 -0.027 -0.209 0.007 0.447 10.000       
B (a) A 0.212 0.121 0.016 -0.125 0.117 -0.293 0.403 0.645 10.000      
Chrys -0.015 0.248 0.171 -0.285 0.655 -0.266 -0.049 -0.125 -0.178 10.000     
B(b)F -0.216 0.707 0.164 -0.292 0.569 -0.432 -0.028 -0.209 0.232 0.481 10.000    
B(k)F 0.000 0.559 0.236 -0.207 0.717 -0.237 -0.013 -0.124 0.083 0.676 0.688 10.000   
B(a)P 0.466 0.218 -0.120 -0.180 0.306 -0.129 0.349 0.635 0.410 0.503 0.290 0.624   10.000  
DB(a,h)A. 098 0.434 0.132 -0.178 0.557 -0.113 -0.020 -0.082 -0.123 0.755 0.525 0.928 0.701 10.000 
 
Correlation at 95% confident level. 
 
 
 
Table 3. Risk Assessment Table of PAHs in ng/mL. 
 
PAH analyte 
ID Carcinogen class Potency/Toxicity Equivalent Factor 
 EPA (2006) IARC (2010) WDNR (2015) Nisbet and LaGoy(1992) BaPn Ratio BaPeq= CnTEFn 
Naphthalene   Nap C 2B - 0.001 0.195 0.00617 
Acenaphthalene  Acl D - - 0.001 0.014 0.00045 
Acenaphthene  Ace - 3 - 0.001 0.027 0.00084 
Fluorene  Flu D 3 - 0.001 0.110 0.00349 
Phenanthrene  Phe D 3 0.001 0.001 0.124 0.00249 
Anthracene  Ant D 3 - 0.001 0.079 0.00392 
Fluoranthene Flt D 3 0.001 0.001 0.081 0.00257 
Pyrene  Pyr D 3 0.001 0.001 0.78 0.02472 
Benz[a]anthracene  Baa B2 2B 0.1 0.1 0.052 0.1640 
Chrysene  Chr B2 2B 0.001 0.01 0.109 0.00346 
Benzo(b)fluoranthene Bbf B2 2B 0.1 0.1 0.136 0.4320 
Benzo(k)fluoranthene Bkf B2 2B 0.01 0.1 0.125 0.0395 
Benzo[a]pyrene  Bap B2 1 1 1 1 31.71 
Dibenzo(a,h)anthracene Dba B2 2A 1 5 0.435 13.79 
 
EPA, Environmental Protection Agency; IARC,  International Agency for Research on Cancer; WDNR, Wisconsin Department of Natural 
Resources; –, Not Available 
 
 
 
(Table 3). For mixtures of PAHs, the reference chemical 
is benzo(a)pyrene, the Toxicity Equivalency Factor for 
each PAH is an estimate of the relative toxicity of the 
PAH compound compared to benzo(a)pyrene (AIOH 
2016). 
    The Toxicity Equivalence Factors (TEF) of PAHs 
together with the WHO Quantitative Risk Assessment 
Model (Ramírez et al., 2011; WHO, 2000) was used to 
estimate the Excess Lifetime Neurology Risk due to PAH 
exposures. Benzo (a) pyrene equivalents (BaPeq) were 
determined by multiplying individual PAH concentrations 
with the corresponding TEF developed by US EPA, 2010 
and Nekhavhambe (2014) based on the toxicity 
equivalent factor of individual PAH. 
 
Thus:  
 
  
BaPeq = (Cn x TEFn)  
 
 
 
 
 
 
Total Toxicity Equivalent factor =  
 
Where, Cn = individual PAH concentration in the complex 
mixture, TEFn = toxic equivalent factor of individual PAH, 
and k = total number of PAH compounds 
The total toxicity of the congeners was calculated on the 
basis of the method for calculating the concentration of 
10 group of PAH to reflect a toxicity equivalent factor 
(TEF) based on benzo(a)pyrene in order to normalize the 
toxicity. Adding the concentrations of the 10 congeners 
together directly will lead to over estimation of the toxicity 
(WDNR, 2015), thus the use of toxicity equivalent factor. 
 The 10 PAHs include Benzo(a)anthracene, Benzo(b) 
fluoranthene, Benzo(g,h,i) perylene, Benzo(k) 
fluoranthene, Chrysene, Dibenzo(a,h)anthracene, 
fluoranthene, indeno(1,2,3-cd)pyrene, phenanthrene  and 
pyrene whose BaPeq should not be more than 0.1 µg/L. 
Only Benzo (g,h,i)perylene and indeno(1,2,3-cd) pyrene 
were not detected in this study. Although the PAHs 
mixture were more than 10 congeners in this study, only 
8 of the congeners were used in the calculation and the 
concentrations totaled 14.459 ng/mL or 14.459 µg/L 
which is well above the expected value of 0.1 µg/L. The 
mixture also reflected all classes of classification of PAHs 
ranging from carcinogenic – probable carcinogen – not 
classifiable. Napthalene has a maximum Concentration 
limit of 70 µg/L in water (since there is no limit set for 
PAHs in the blood by any standard organization), but the 
mean value in this study was 6.17 µg/L. Maximum 
Contamination Level(MCL) of some PAHs in water given 
by USEPA (1984) were 0.2 ng/mL for Benzo(a)pyrene, 
Benzo(b)fluoranthene, Benzo(k)fluoranthene and 
chrysene while Benz[a]anthracene and Dibenzo(a,h) 
anthracene were given MCL of 0.1 ng/mL and 0.3 ng/mL 
respectively. The mean values for these PAHs were 
found to be higher in the plasma of the neurology 
patients. The non-classifiable member of PAHs is 
capable of causing problem(s) at a high concentration 
which may not be known for now.  
 
 
Conclusion 
 
The study shows that the concentration levels of the 
PAHs detected in the plasma samples of the neurology 
patients are significantly higher at 95 % level than the 
control samples.  The MCL values provided for water and 
the literature values of the similar research were lower in 
concentration than what was found in the neurology 
patients. Volatile PAHs are most prevalent in the samples 
and there was high correlation in the concentrations of 
the volatile congeners, thus, they could be used as 
biomarkers  in  the  blood/plasma   analysis.   This   result  
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represents a veritable baseline study of PAHs in 
Neurology Patients in the country. Further work could be 
done in assessing the level of these PAHs in the same 
group of patients as they continue their treatment, and 
also to further establish the actual roles of these 
congeners in the causation of these neurological 
diseases. This can further open up a new vista in 
therapeutic approaches to treatment. 
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